Stanozolol (Winstrol) – Alleviates the Rheumatoid Arthritis Symptoms

…and perhaps also psoriasis symptoms.

First I have to say that I am not promoting stanozolol use for rheumatoid arthritis, psoriasis or psoriatic arthritis. This is a synthetic anabolic steroid with many serious (side) effects like liver and kidney damage amongst the others. The purpose of this article is just to put together some information about stanozolol and describe the relation between this anabolic steroid, fibrin and low oxygenation of the body and some diseases that medicine considers as autoimmune.

The anabolic steroid stanozolol is highly popular between the athletes and bodybuilders where it is known under the name Winstrol. It is a synthetic C17 alpha-alkylated derivative of dihydrotestosterone (DHT). Despite the fact that it is not a popular drug in medicine the scientific studies show the positive effect of stanozolol when taken is appropriate amounts for rheumatoid arthritis.

Fibrin deposition in rheumatoid arthritis

Fibrinolytic effects of stanozolol are documented in many scientific studies.[3] One study concluded that fibrin generated inside the joint cavity may be the cause of synovial fibroblast (joint cell) activation what plays a role in rheumatoid arthritis.[5]

When we consider the fibrin deposition in joint as a cause (or at least worsening factor) of rheumatoid arthritis then we should try to fight off that fibrin formation and deposition to improve the symptoms of this chronic disease. That’s exactly what did the authors of one study and concluded that there is a marked fibrinolytic effect of stanozolol when taken 10 mg per day for 12 months.[6]

Fibrin in the blood

Another supportive study confirmed that the fibrinolysis leads to alleviation of rheumatoid arthritis symptoms. That study was published in 1986.[2]

The title of that study – “The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.” – speaks for itself. The authors decided to test the effect of dissolving the fibrin deposits with stanozolol in people with rheumatoid arthritis to find out how exactly does it affect the symptoms of their arthritis condition.

The authors of the study built their research on the proven fact that fibrinolysis is decreased in people with severe rheumatoid arthritis. Therefore they decided to try use the stanozolol as a fibrinolisys enhancing drug to treat the rheumatoid arthritis. Total of 40 patients were enrolled in the study – 20 patients received stanozolol 5 mg twice daily and the control group of another 20 patients received a placebo for 6 months.

After the six month period of the study 9 control patients decided to withdrawn because they felt like the drug was ineffective. However only two people from the stanozolol group decided to end because of feeling that the drug didn’t work for them.

However 5 patients from the control group said that their condition improved compared to 15 stanozolol group patients who said they feel better.

Activity of the disease significantly improved in treated group: ESR (erythrocyte sedimentation rate – fibrinogen in blood significantly affects this parameter), joint tenderness, duration of morning stiffness and pain.

  • plasminogen – precursor of plasmin (plasminogen is converted to plasmin by Plasminogen Activator)
  • thrombin – enzyme that causes fibrin formation
  • fibrinogen – glycoprotein that is converted to fibrin by thrombin
  • plasmin – enzyme degrading the fibrin 

    Another detailed study about the

    There is still another 434 words in this article!

    You may also like...

    Leave a Reply

    Your email address will not be published.

    This site uses Akismet to reduce spam. Learn how your comment data is processed.